









137		(S)-5-(1-(3-aminocyclobutyl)-5-(3,5-dimethylisoxazol-4-yl)-1 <i>H</i> -benzo[<i>d</i>]imidazol-2-yl)-1-(3,4-difluorophenyl)pyrrolidin-2-one
138		(S)-1-(3,4-difluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-(thiazol-4-ylmethyl)-1 <i>H</i> -benzo[<i>d</i>]imidazol-2-yl)pyrrolidin-2-one
139		(S)-5-(1-(3-carboxycyclobutyl)-5-(3,5-dimethylisoxazol-4-yl)-1 <i>H</i> -benzo[<i>d</i>]imidazol-2-yl)-1-(3,4-difluorophenyl)pyrrolidin-2-one

143		(S)-5-(1-((R)-3,3-difluorocyclopentyl)-5-(3,5-dimethylisoxazol-4-yl)-1H-benzo[d]imidazol-2-yl)-1-(3-chloro-4-methoxyphenyl)pyrrolidin-2-one
144		(5S)-1-(3,4-difluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-(2-hydroxypropyl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one (diastereoisomer 1)
145		(5S)-1-(3,4-difluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-(2-hydroxypropyl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one (diastereoisomer 2)
146		(R)-1-(3,4-dichlorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-(methylsulfonyl)piperidin-3-yl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one



A solution of DBU (20 μ L, 0.133 mmol) and **Intermediate E1** (60 mg, 0.129 mmol) in acetonitrile (4 mL) was added to a vial charged with CuTMEDA (10 mg, 0.022 mmol) and (4-(trifluoromethyl)phenyl)boronic acid (28 mg, 0.147 mmol) before stirring for 18 h at 40°C. The mixture was diluted with water then extracted with dichloromethane (3 x 8 mL). The organic phases were combined then filtered and concentrated under reduced pressure. The crude product was purified by chromatography on the Companion (4 g column, 2-5% MeOH/DCM) to afford (*S*)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((*R*)-1-(methylsulfonyl)pyrrolidin-3-yl)-1*H*-benzo[*d*]imidazol-2-yl)-1-(4-(trifluoromethyl)phenyl)pyrrolidin-2-one (42 mg, 54%) as a pale yellow glass; Rt 2.09 min (method 1), *m/z* 588 (*M*+*H*)⁺ (*ES*⁺); ¹H NMR (d₆-DMSO) δ : 7.83 - 7.73 (m, 3H), 7.73 - 7.65 (m, 2H), 7.63 (d, *J* = 1.6 Hz, 1H), 7.26 (dd, *J* = 8.4, 1.7 Hz, 1H), 6.21 - 6.12 (m, 1H), 5.63 - 5.48 (m, 1H), 3.88 - 3.78 (m, 1H), 3.78 - 3.64 (m, 2H), 3.46 - 3.36 (m, 1H), 3.10 (s, 3H), 2.79 - 2.54 (m, 5H), 2.37 (s, 3H), 2.25 - 2.14 (m, 1H), 2.20 (s, 3H); Chiral HPLC (Diacel Chiralpak IA, 5 μ m, 4.6x250 mm, 30 min method, 1.0 mL/min, isocratic 30% EtOH in isohexane (0.2% TFA): RT = 7.19 min, >99%, >98% de @ 254 nm.


Example 32: (*S*)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((*R*)-1-(methylsulfonyl)pyrrolidin-3-yl)-1*H*-benzo[*d*]imidazol-2-yl)-1-(4-(trifluoromethoxy)phenyl)pyrrolidin-2-one

(*S*)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((*R*)-1-(methylsulfonyl)pyrrolidin-3-yl)-1*H*-benzo[*d*]imidazol-2-yl)-1-(4-(trifluoromethoxy)phenyl)pyrrolidin-2-one

1H), 3.75 (s, 3H), 2.82 - 2.42 (m, 7H), 2.37 (s, 3H), 2.34 - 2.22 (m, 2H), 2.20 (s, 3H), 2.15 - 2.07 (m, 1H).

Example 143: (*S*)-5-(1-((*R*)-3,3-difluorocyclopentyl)-5-(3,5-dimethylisoxazol-4-yl)-1*H*-benzo[*d*]imidazol-2-yl)-1-(3-chloro-4-methoxyphenyl)pyrrolidin-2-one

(*S*)-5-(1-((*R*)-3,3-difluorocyclopentyl)-5-(3,5-dimethylisoxazol-4-yl)-1*H*-benzo[*d*]imidazol-2-yl)-1-(3-chloro-4-methoxyphenyl)pyrrolidin-2-one



10 CuTMEDA (29.0 mg, 0.062 mmol) was added to a stirred solution of (*S*)-5-(1-((*R*)-3,3-difluorocyclopentyl)-5-(3,5-dimethylisoxazol-4-yl)-1*H*-benzo[*d*]imidazol-2-yl)pyrrolidin-2-one (50 mg, 0.125 mmol) in pyridine (1.50 mL, 18.61 mmol) then the mixture was stirred for 15 min at 40°C. (3-Chloro-4-methoxyphenyl)boronic acid (61.7 mg, 0.331 mmol) was added then the mixture was heated to 40°C for 2 h. The reaction


15 was cooled down to RT and the mixture was diluted with ethyl acetate (20 mL) then washed with water (3 x 10 mL). The organic phase was then filtered through a PhaseSep cartridge and concentrated under reduced pressure. The residue was taken up in DCM purified by chromatography on the Companion (4 g column, 0-10% (10% MeOH in DCM) in DCM, gradient elution). After concentration of the combined

20 fractions, diethyl ether (10mL) was added and the suspension was concentrated *in vacuo* to afford (*S*)-1-(3-chloro-4-methoxyphenyl)-5-(1-((*R*)-3,3-difluorocyclopentyl)-5-(3,5-dimethylisoxazol-4-yl)-1*H*-benzo[*d*]imidazol-2-yl)pyrrolidin-2-one (52 mg, 75%) as a white foam; Rt 2.28 min; m/z 541 (M+H)⁺ (ES⁺); 1H NMR (d₆-DMSO) δ: 7.79 (dd, J = 3.9, 2.6 Hz, 1H), 7.65 (d, 1H), 7.61 (t, J = 8.4 Hz, 1H), 7.33 - 7.21 (m, 2H), 7.07 (dd, J = 9.1, 2.9 Hz, 1H), 6.06 (td, J = 8.6 Hz, 1H), 5.42 (q, J = 9.2 Hz, 1H), 3.77 (s, 3H),

25 2.82 - 2.40 (m, 7H), 2.37 (s, 3H), 2.34 - 2.22 (m, 2H), 2.20 (s, 3H), 2.18 - 2.07 (m, 1H).

Example 139: (*S*)-5-(1-(3-aminocyclobutyl)-5-(3,5-dimethylisoxazol-4-yl)-1*H*-benzo[*d*]imidazol-2-yl)-1-(3,4-difluorophenyl)pyrrolidin-2-one


5 (*S*)-5-(1-(3- carboxycyclobutyl)-5-(3,5-dimethylisoxazol-4-yl)-1*H*- benzo[*d*]imidazol-2-yl)-1-(3,4-difluorophenyl)pyrrolidin-2-one



To a mixture of (*S*)-*N*-(2-amino-5-(3,5-dimethylisoxazol-4-yl)phenyl)-1-(3,4-difluorophenyl)-5-oxopyrrolidine-2-carboxamide (0.094 ml, 0.176 mmol) and DCM
 10 (1.5 mL, 23.31 mmol) were added 3-oxocyclobutanecarboxylic acid (26.1 mg, 0.229 mmol) and acetic acid (0.75 mL, 13.10 mmol) . The mixture was stirred at room temperature for 20 minutes then pyridine borane (0.037 mL, 0.352 mmol) was added. The mixture was stirred at room temperature for 1 hour. A few drops of concentrated HCl were added and stirring continued at RT for 5 min. Then acetic acid (0.75 mL,
 15 13.10 mmol) was added and the mixture was stirred at 80 °C for 18 hr. The mixture was concentrated under reduced pressure. The crude product was purified by chromatography on silica gel (12 g column, 0-5% MeOH/DCM) to afford (*S*)-3-(2-(1-(3,4-difluorophenyl)-5-oxopyrrolidin-2-yl)-5-(3,5-dimethylisoxazol-4-yl)-1*H*-benzo[*d*]imidazol-1-yl)cyclobutanecarboxylic acid (40 mg, 43%) as a tanned solid; Rt 1.91 min
 20 (method 1), *m/z* 507 (*M*+*H*)⁺ (*ES*⁺); ¹H NMR (d₆-DMSO) δ: 8.45 (d, *J* = 8.5 Hz, 0.5H), 8.12 (t, *J* = 5.7 Hz, 0.5H), 7.96 (t, *J* = 5.7 Hz, 0.5H), 7.91 (d, *J* = 8.4 Hz, 0.5H), 7.87 - 7.74 (m, 1H), 7.64-7.60 (m, 1H), 7.47 - 7.31 (m, 1H), 7.30 - 7.11 (m, 1H), 6.05 (d, *J* = 7.8 Hz, 0.5H), 5.97 (d, *J* = 7.0 Hz, 0.5H), 5.44-5.32 (m, 0.5H), 5.30 - 5.20 (m, 0.5H), 3.16 - 3.07 (m, 5H), 3.06 - 2.91 (m, 1H), 2.77 - 2.58 (m, 4H), 2.38 (2 x s, 3H),
 25 2.22 (2 x s, 3H), 2.12 - 2.00 (m, 2H), 1.53 - 1.39 (m, 2H), 0.93 - 0.84 (m, 3H).

CLAIMS

1. A compound which is an arylimidazolyl isoxazole of formula (I):




in which:

- 5 R^0 and R , which are the same or different, are each H or C_1 - C_6 alkyl which is unsubstituted or substituted by OH, $-OC(O)R'$ or OR' in which R' is unsubstituted C_1 - C_6 alkyl;

W is N or CH;

- 10 R^1 is a group which is unsubstituted or substituted and is selected from C-linked 4- to 6-membered heterocyclyl; C_3 - C_6 cycloalkyl; C_1 - C_6 alkyl which is unsubstituted or substituted by C_6 - C_{10} aryl, 5- to 12-membered N-containing heteroaryl, C_3 - C_6 cycloalkyl, OH, $-OC(O)R'$ or OR' in which R' is as defined above; and a spiro group of the following formula:




- 15 Y is $-CH_2-$, $-CH_2CH_2-$ or $-CH_2CH_2CH_2-$;

n is 0 or 1;

R^2 is a group selected from C_6 - C_{10} aryl, 5- to 12-membered N-containing heteroaryl, C_3 - C_6 cycloalkyl and C_5 - C_6 cycloalkenyl, in which the group is unsubstituted or substituted and in which C_6 - C_{10} aryl is optionally fused to a 5- or 6-membered heterocyclic ring;

or a pharmaceutically acceptable salt thereof.

2. A compound according to Claim 1, in which the arylimidazolyl isoxazole has the following formula (Ia):




5 in which

R^1 is as defined in Claim 1;

Y' is $-CH_2-$ or $-CH_2CH_2-$; and

10 $R^{2'}$ is a group selected from C_6-C_{10} aryl optionally fused to a 5- or 6-membered heterocyclic ring and C_5-C_6 heteroaryl, the group being unsubstituted or mono-, di- or tri-substituted.

3. A compound according to Claim 1 or 2 in which R^1 is selected from the following structures:



4. A compound according to any preceding claim which is the S enantiomer (based on the chiral C atom of the pyrrolidin-2-one or piperidin-2-one ring).

5. A compound according to Claim 1 which is selected from:

5-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-(methylsulfonyl)pyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)-1-phenylpyrrolidin-2-one;

5-(5-(3,5-dimethylisoxazol-4-yl)-1-(tetrahydro-2H-pyran-4-yl)-1H-benzo[d]imidazol-2-yl)-1-phenylpyrrolidin-2-one;

10 5-(5-(3,5-dimethylisoxazol-4-yl)-1-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-1H-benzo[d]imidazol-2-yl)-1-phenylpyrrolidin-2-one;

(S)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-(methylsulfonyl)pyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)-1-phenylpyrrolidin-2-one;

15 (R)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-(methylsulfonyl)pyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)-1-phenylpyrrolidin-2-one;

(S)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-(methylsulfonyl)pyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)-1-(3-fluorophenyl)pyrrolidin-2-one;

(S)-1-(3,4-difluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-(methylsulfonyl)pyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;

5 (S)-1-(4-chloro-3-fluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-(methylsulfonyl)pyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;

(S)-1-(3-chloro-4-fluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-(methylsulfonyl)pyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;

10 (S)-1-(3,5-dichlorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-(methylsulfonyl)pyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;

(S)-1-(3-chloro-5-fluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-(methylsulfonyl)pyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;

(S)-1-(3-chloro-5-methoxyphenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-(methylsulfonyl)pyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;

15 (S)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-(methylsulfonyl)pyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)-1-(3-fluoro-4-methoxyphenyl)pyrrolidin-2-one;

(S)-1-(3-chloro-4-methoxyphenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-(methylsulfonyl)pyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;

20 (S)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-(methylsulfonyl)pyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)-1-(4-methoxyphenyl)pyrrolidin-2-one;

(S)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-(methylsulfonyl)pyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)-1-(4-propoxyphenyl)pyrrolidin-2-one;

(S)-1-(4-chlorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-(methylsulfonyl)pyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;

25 (S)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-(methylsulfonyl)pyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)-1-(pyridin-3-yl)pyrrolidin-2-one;

(S)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-(methylsulfonyl)pyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)-1-(6-fluoropyridin-3-yl)pyrrolidin-2-one;

- (S)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-(methylsulfonyl)pyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)-1-(naphthalen-1-yl)pyrrolidin-2-one;
- (S)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-(methylsulfonyl)pyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)-1-(5-fluoropyridin-3-yl)pyrrolidin-2-one;
- 5 (S)-1-(3,5-difluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-(methylsulfonyl)pyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- (S)-1-(5-chloro-6-methoxypyridin-3-yl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-(methylsulfonyl)pyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- 10 (S)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-(methylsulfonyl)pyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)-1-(3-fluoro-5-methoxyphenyl)pyrrolidin-2-one;
- (S)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-(methylsulfonyl)pyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)-1-(3-(trifluoromethoxy)phenyl)pyrrolidin-2-one;
- (S)-1-(2,3-dihydrobenzofuran-5-yl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-(methylsulfonyl)pyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- 15 (S)-1-(3,4-dichlorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-(methylsulfonyl)pyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- (S)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-(methylsulfonyl)pyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)-1-(6-methoxypyridin-3-yl)pyrrolidin-2-one;
- (S)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-(methylsulfonyl)pyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)-1-(3,4,5-trifluorophenyl)pyrrolidin-2-one;
- 20 (S)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-(methylsulfonyl)pyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)-1-(4-(trifluoromethyl)phenyl)pyrrolidin-2-one;
- (S)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-(methylsulfonyl)pyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)-1-(4-(trifluoromethoxy)phenyl)pyrrolidin-2-one;
- 25 (S)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-(methylsulfonyl)pyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)-1-(3-ethoxy-5-fluorophenyl)pyrrolidin-2-one;
- (S)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-(methylsulfonyl)pyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)-1-(o-tolyl)pyrrolidin-2-one;

(S)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-(methylsulfonyl)pyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)-1-(5-fluoro-2-methylphenyl)pyrrolidin-2-one;

3-((S)-2-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-(methylsulfonyl)pyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)-5-oxopyrrolidin-1-yl)-5-fluorobenzonitrile;

5 (S)-1-(cyclohex-1-en-1-yl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-(methylsulfonyl)pyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one ;

(S)-1-(4,5-difluoro-2-methylphenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-(methylsulfonyl)pyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one ;

10 (S)-1-(3,4-dichloro-2-methylphenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-(methylsulfonyl)pyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;

(R)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-(methylsulfonyl)pyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)-1-(3-fluorophenyl)pyrrolidin-2-one;

(R)-1-(3,4-difluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-(methylsulfonyl)pyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;

15 (R)-1-(4-chloro-3-fluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-(methylsulfonyl)pyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;

(R)-1-(3,5-dichlorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-(methylsulfonyl)pyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;

20 (R)-1-(3-chloro-4-fluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-(methylsulfonyl)pyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;

(R)-1-(3-chloro-5-fluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-(methylsulfonyl)pyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;

(S)-1-(3,4-difluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;

25 (S)-1-(3-chloro-4-fluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;

(S)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-1H-benzo[d]imidazol-2-yl)-1-(3-fluorophenyl)pyrrolidin-2-one;

- (S)-1-(4-chloro-3-fluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- (S)-1-(3-chloro-5-methoxyphenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- 5 (S)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-1H-benzo[d]imidazol-2-yl)-1-(3-fluoro-4-methoxyphenyl)pyrrolidin-2-one;
- (S)-1-(3-chloro-4-methoxyphenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- 10 (S)-1-(3,5-dichlorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- (S)-1-(3-chloro-5-fluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- (S)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-1H-benzo[d]imidazol-2-yl)-1-(3,4,5-trifluorophenyl)pyrrolidin-2-one;
- 15 (S)-1-(3,5-difluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- (S)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-1H-benzo[d]imidazol-2-yl)-1-(5-fluoro-6-methoxypyridin-3-yl)pyrrolidin-2-one;
- (S)-1-(2,3-dihydrobenzofuran-5-yl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- 20 (S)-1-(3,4-dichlorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- (S)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((1*r*,4*S*)-4-hydroxycyclohexyl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- 25 (S)-1-(3,4-difluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((1*r*,4*S*)-4-hydroxycyclohexyl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- (S)-1-(4-chloro-3-fluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((1*r*,4*S*)-4-hydroxycyclohexyl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;

- (S)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((1*r*,4*S*)-4-hydroxycyclohexyl)-1*H*-benzo[d]imidazol-2-yl)-1-(3-fluoro-4-methoxyphenyl)pyrrolidin-2-one;
- (S)-1-(3-chloro-4-methoxyphenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((1*r*,4*S*)-4-hydroxycyclohexyl)-1*H*-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- 5 (S)-1-(3-chloro-4-fluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((1*r*,4*S*)-4-hydroxycyclohexyl)-1*H*-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- (S)-1-(2,3-dihydrobenzofuran-5-yl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((1*r*,4*S*)-4-hydroxycyclohexyl)-1*H*-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- (S)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((1*r*,4*S*)-4-hydroxycyclohexyl)-1*H*-benzo[d]imidazol-2-yl)-1-(naphthalen-1-yl)pyrrolidin-2-one;
- 10 (S)-1-(3,4-dichlorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-(4-hydroxycyclohexyl)-1*H*-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- (S)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((S)-1,1-dioxidotetrahydrothiophen-3-yl)-1*H*-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- 15 (S)-1-(3,4-difluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((S)-1,1-dioxidotetrahydrothiophen-3-yl)-1*H*-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- Tert-butyl (S)-3-(2-((S)-1-(3,4-difluorophenyl)-5-oxopyrrolidin-2-yl)-5-(3,5-dimethylisoxazol-4-yl)-1*H*-benzo[d]imidazol-1-yl)pyrrolidine-1-carboxylate;
- Tert*-butyl (*R*)-3-(2-((S)-1-(3,4-difluorophenyl)-5-oxopyrrolidin-2-yl)-5-(3,5-dimethylisoxazol-4-yl)-1*H*-benzo[d]imidazol-1-yl)pyrrolidine-1-carboxylate;
- 20 (S)-1-(3,4-difluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((S)-1-(methylsulfonyl)pyrrolidin-3-yl)-1*H*-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- (S)-5-(1-((*R*)-1-(cyclopropylsulfonyl) pyrrolidin-3-yl)-5-(3,5-dimethylisoxazol-4-yl)-1*H*-benzo[d]imidazol-2-yl)-1-(3,4-difluorophenyl) pyrrolidin-2-one;
- 25 (S)-5-(1-((*R*)-1-acetylpyrrolidin-3-yl)-5-(3,5-dimethylisoxazol-4-yl)-1*H*-benzo[d]imidazol-2-yl)-1-(3,4-difluorophenyl)pyrrolidin-2-one;
- (S)-1-(3,4-difluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((*R*)-1-(3,3,3-trifluoropropanoyl)pyrrolidin-3-yl)-1*H*-benzo[d]imidazol-2-yl)pyrrolidin-2-one;

- (5S)-1-(3,4-difluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-(1-methylpyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- (5S)-1-(4-chloro-3-fluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-(1-methylpyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- 5 (5S)-1-(3,4-dichlorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-(1-methylpyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- (S)-1-(3,4-dichlorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((1*r*,4*S*)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- (S)-1-(3,4-difluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((1*r*,4*S*)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- 10 (S)-1-(3-chloro-4-methoxyphenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((1*r*,4*S*)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- (S)-1-(2,3-dihydrobenzofuran-5-yl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((1*r*,4*S*)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- 15 (S)-1-(3-chloro-4-fluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((1*r*,4*S*)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- (S)-1-(4-chloro-3-fluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((1*r*,4*S*)-4-methoxycyclohexyl)-1*H*-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- (S)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((1*r*,4*S*)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-1-(3-fluoro-4-methoxyphenyl)pyrrolidin-2-one;
- 20 (S)-1-(3,4-difluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((1*s*,4*R*)-4-hydroxycyclohexyl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- (S)-1-(3,4-difluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((1*s*,4*R*)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- 25 (S)-1-(3,4-difluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((1*R*,4*s*)-4-ethoxycyclohexyl)-1*H*-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- (5S)-1-(3,4-dichlorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-(1,1-dioxidotetrahydro-2H-thiopyran-3-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;

- (5S)-1-(4-chloro-3-fluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-(1,1-dioxidotetrahydro-2H-thiopyran-3-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- (5S)-1-(3-chloro-4-methoxyphenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-(1,1-dioxidotetrahydro-2H-thiopyran-3-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- 5 (5S)-1-(2,3-dihydrobenzofuran-5-yl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-(1,1-dioxidotetrahydro-2H-thiopyran-3-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- (S)-1-(3,4-dichlorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-(1-(methylsulfonyl)piperidin-4-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- (S)-1-(4-chloro-3-fluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-(1-(methylsulfonyl)piperidin-4-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- 10 (S)-1-(3-chloro-4-methoxyphenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-(1-(methylsulfonyl)piperidin-4-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- (S)-1-(2,3-dihydrobenzofuran-5-yl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-(1-(methylsulfonyl)piperidin-4-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- 15 (S)-1-(3,4-difluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-(1-(methylsulfonyl)piperidin-4-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- (S)-1-(3-chloro-4-fluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-(1-(methylsulfonyl)piperidin-4-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- (S)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-(1-(methylsulfonyl)piperidin-4-yl)-1H-benzo[d]imidazol-2-yl)-1-(3-fluoro-4-methoxyphenyl)pyrrolidin-2-one;
- 20 (S)-1-(4-chloro-3-fluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((1R,3R)-3-hydroxycyclopentyl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one ;
- (S)-1-(3-chloro-4-methoxyphenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((1R,3R)-3-hydroxycyclopentyl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- 25 (S)-1-(3,4-dichlorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((1R,3R)-3-hydroxycyclopentyl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- (1R,3R)-3-(2-((S)-1-(3,4-difluorophenyl)-5-oxopyrrolidin-2-yl)-5-(3,5-dimethylisoxazol-4-yl)-1H-benzo[d]imidazol-1-yl)cyclopentyl acetate;

(1R,3R)-3-(2-((S)-1-(3-chloro-4-methoxyphenyl)-5-oxopyrrolidin-2-yl)-5-(3,5-dimethylisoxazol-4-yl)-1H-benzo[d]imidazol-1-yl)cyclopentyl acetate;

(S)-1-(3-chloro-4-methoxyphenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-(1r,3r)-3-methoxycyclopentyl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;

5 (S)-1-(3,4-dichlorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-(1r,3r)-3-methoxycyclopentyl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;

(S)-1-(4-chloro-3-fluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-(1r,3r)-3-methoxycyclopentyl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;

10 (S)-1-(3,4-difluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-(1r,3r)-3-methoxycyclopentyl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;

(S)-5-(1-(4,4-difluorocyclohexyl)-5-(3,5-dimethylisoxazol-4-yl)-1H-benzo[d]imidazol-2-yl)-1-(3,4-difluorophenyl)pyrrolidin-2-one ;

(S)-1-(3-chloro-4-methoxyphenyl)-5-(1-(4,4-difluorocyclohexyl)-5-(3,5-dimethylisoxazol-4-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;

15 (S)-1-(3-fluoro-4-methoxyphenyl)-5-(1-(4,4-difluorocyclohexyl)-5-(3,5-dimethylisoxazol-4-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;

(5S)-1-(3,4-difluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-(2-methyltetrahydro-2H-pyran-4-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;

20 (5S)-1-(3-chloro-4-methoxyphenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-(2-methyltetrahydro-2H-pyran-4-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;

(5S)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-(2-methyltetrahydro-2H-pyran-4-yl)-1H-benzo[d]imidazol-2-yl)-1-(3-fluoro-4-methoxyphenyl)pyrrolidin-2-one;

5-(2-((S)-1-(3,4-difluorophenyl)-5-oxopyrrolidin-2-yl)-5-(3,5-dimethylisoxazol-4-yl)-1H-benzo[d]imidazol-1-yl)piperidin-2-one;

25 (S)-1-(3,4-difluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;

(S)-1-(3,4-difluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((1s,4R)-4-hydroxy-4-methylcyclohexyl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;

- (S)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((1s,4R)-4-hydroxy-4-methylcyclohexyl)-1H-benzo[d]imidazol-2-yl)-1-(3-fluoro-4-methoxyphenyl)pyrrolidin-2-one;
- (S)-1-(3,4-dichlorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((1s,4R)-4-hydroxy-4-methylcyclohexyl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- 5 (S)-1-(4-chloro-3-fluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((1s,4R)-4-hydroxy-4-methylcyclohexyl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- (S)-1-(3-chloro-4-methoxyphenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-(2-oxaspiro[3.3]heptan-6-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- (S)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-(2-oxaspiro[3.3]heptan-6-yl)-1H-benzo[d]imidazol-2-yl)-1-(3-fluoro-4-methoxyphenyl)pyrrolidin-2-one;
- 10 (S)-1-(3,4-difluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,3S)-3-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- (1S,3r)-3-(2-((S)-1-(3,4-difluorophenyl)-5-oxopyrrolidin-2-yl)-5-(3,5-dimethylisoxazol-4-yl)-1H-benzo[d]imidazol-1-yl)cyclobutyl acetate;
- 15 (S)-5-(1-benzyl-5-(3,5-dimethylisoxazol-4-yl)-1H-benzo[d]imidazol-2-yl)-1-(3,4-difluorophenyl)pyrrolidin-2-one;
- (S)-1-(3,4-difluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-propyl-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- (S)-1-(3,4-difluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-isobutyl-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- 20 (S)-1-(3,4-difluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- (S)-5-(1-((4,4-difluorocyclohexyl)methyl)-5-(3,5-dimethylisoxazol-4-yl)-1H-benzo[d]imidazol-2-yl)-1-(3,4-difluorophenyl)pyrrolidin-2-one;
- 25 (S)-5-(1-benzyl-5-(3,5-dimethylisoxazol-4-yl)-1H-benzo[d]imidazol-2-yl)-1-(3-fluoro-4-methoxyphenyl)pyrrolidin-2-one;
- (S)-1-(3,4-difluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-(pyridin-3-ylmethyl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;

- (S)-1-(3,4-difluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((1s,3R)-3-(hydroxymethyl)cyclobutyl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- (S)-1-(3,4-difluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,3S)-3-(hydroxymethyl)cyclobutyl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- 5 (S)-5-(1-(cyclopropylmethyl)-5-(3,5-dimethylisoxazol-4-yl)-1H-benzo[d]imidazol-2-yl)-1-(3,4-difluorophenyl)pyrrolidin-2-one;
- (S)-3-(2-(1-(3,4-difluorophenyl)-5-oxopyrrolidin-2-yl)-5-(3,5-dimethylisoxazol-4-yl)-1H-benzo[d]imidazol-1-yl)propyl acetate;
- (S)-5-(1-(3-aminocyclobutyl)-5-(3,5-dimethylisoxazol-4-yl)-1H-benzo[d]imidazol-2-yl)-1-(3,4-difluorophenyl)pyrrolidin-2-one;
- 10 (S)-1-(3,4-difluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-(thiazol-4-ylmethyl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- (S)-5-(1-(3-carboxycyclobutyl)-5-(3,5-dimethylisoxazol-4-yl)-1H-benzo[d]imidazol-2-yl)-1-(3,4-difluorophenyl)pyrrolidin-2-one;
- 15 (S)-3-(2-(1-(3,4-difluorophenyl)-5-oxopyrrolidin-2-yl)-5-(3,5-dimethylisoxazol-4-yl)-1H-benzo[d]imidazol-1-yl)-N-propylcyclobutanecarboxamide;
- (S)-5-(1-((R)-3,3-difluorocyclopentyl)-5-(3,5-dimethylisoxazol-4-yl)-1H-benzo[d]imidazol-2-yl)-1-(3,4-difluorophenyl)pyrrolidin-2-one;
- (S)-5-(1-((R)-3,3-difluorocyclopentyl)-5-(3,5-dimethylisoxazol-4-yl)-1H-benzo[d]imidazol-2-yl)-1-(3-fluoro-4-methoxyphenyl)pyrrolidin-2-one;
- 20 (S)-5-(1-((R)-3,3-difluorocyclopentyl)-5-(3,5-dimethylisoxazol-4-yl)-1H-benzo[d]imidazol-2-yl)-1-(3-chloro-4-methoxyphenyl)pyrrolidin-2-one;
- (5S)-1-(3,4-difluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-(2-hydroxypropyl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one; (diastereoisomer 1)
- 25 (5S)-1-(3,4-difluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-(2-hydroxypropyl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one; (diastereoisomer 2)
- (R)-1-(3,4-dichlorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-(methylsulfonyl)pyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one;

- (S)-1-(3,4-dichlorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-(methylsulfonyl)pyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one;
- (S)-1-(4-chloro-3-fluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-(methylsulfonyl)pyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one;
- 5 (S)-1-(3,4-difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-(methylsulfonyl)pyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one;
- (S)-1-(3-chloro-4-methoxyphenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-(methylsulfonyl)pyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one;
- (S)-1-(3-fluoro-4-methoxyphenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-(methylsulfonyl)pyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one;
- 10 (S)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1*r*,4*S*)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-1-(3,4-di-fluorophenyl)piperidin-2-one ;
- (S)-1-(4-chloro-3-fluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1*r*,4*S*)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one;
- 15 (S)-1-(3-chloro-4-methoxyphenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1*r*,4*S*)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one;
- (S)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1*r*,4*S*)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-1-(3-fluoro-4-methoxyphenyl)piperidin-2-one;
- (S)-1-(3,4-difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1*s*,4*R*)-4-hydroxy-4-methylcyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one;
- 20 (S)-1-(3-chloro-4-methoxyphenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1*s*,4*R*)-4-hydroxy-4-methylcyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one;
- (S)-1-(3,4-dichlorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1*s*,4*R*)-4-hydroxy-4-methylcyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one;
- 25 (S)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1*s*,4*R*)-4-hydroxy-4-methylcyclohexyl)-1H-benzo[d]imidazol-2-yl)-1-(3-fluoro-4-methoxyphenyl)piperidin-2-one;
- (S)-1-(4-chloro-3-fluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1*s*,4*R*)-4-hydroxy-4-methylcyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one;

- (S)-1-(3,4-difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,3S)-3-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one;
- (S)-1-(3-chloro-4-methoxyphenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,3S)-3-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one;
- 5 (S)-1-(3,4-dichlorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,3S)-3-hydroxycyclobutyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one;
- (S)-1-(3,4-difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-hydroxy-4-methylcyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one;
- (S)-1-(3-chloro-4-methoxyphenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-hydroxy-4-methylcyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one;
- 10 (S)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-hydroxy-4-methylcyclohexyl)-1H-benzo[d]imidazol-2-yl)-1-(3-fluoro-4-methoxyphenyl)piperidin-2-one;
- (S)-1-(3,4-dichlorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-isobutyl-1H-benzo[d]imidazol-2-yl)piperidin-2-one;
- 15 (S)-1-(3-chloro-4-methoxyphenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-isobutyl-1H-benzo[d]imidazol-2-yl)piperidin-2-one;
- (S)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-isobutyl-1H-benzo[d]imidazol-2-yl)-1-(3-fluoro-4-methoxyphenyl)piperidin-2-one;
- (S)-6-(1-(4,4-difluorocyclohexyl)-5-(3,5-dimethylisoxazol-4-yl)-1H-benzo[d]imidazol-2-yl)-1-(3-fluoro-4-methoxyphenyl)piperidin-2-one;
- 20 (S)-6-(1-(4,4-difluorocyclohexyl)-5-(3,5-dimethylisoxazol-4-yl)-1H-benzo[d]imidazol-2-yl)-1-(3,4-difluorophenyl)piperidin-2-one;
- (S)-1-(3-chloro-4-methoxyphenyl)-6-(1-(4,4-difluorocyclohexyl)-5-(3,5-dimethylisoxazol-4-yl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one;
- 25 (S)-1-(3,4-dichlorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-hydroxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one;
- (S)-1-(3,4-difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-hydroxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one;

- (S)-1-(3-chloro-4-methoxyphenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1*r*,4*S*)-4-hydroxycyclohexyl)-1*H*-benzo[d]imidazol-2-yl)piperidin-2-one;
- (S)-1-(3,4-difluorophenyl)-5-(1-((1*r*,4*S*)-4-hydroxycyclohexyl)-5-(5-(hydroxymethyl)-3-methylisoxazol-4-yl)-1*H*-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- 5 (S)-1-(3,4-difluorophenyl)-5-(1-((1*r*,4*S*)-4-hydroxycyclohexyl)-5-(3-(hydroxymethyl)-5-methylisoxazol-4-yl)-1*H*-benzo[d]imidazol-2-yl)pyrrolidin-2-one;
- (S)-6-(1-(4,4-difluorocyclohexyl)-5-(3,5-dimethylisoxazol-4-yl)-1*H*-benzo[d]imidazol-2-yl)-1-phenylpiperidin-2-one;
- (S)-1-(3-chloro-4-methoxyphenyl)-6-(1-(3,3-difluorocyclobutyl)-5-(3,5-dimethylisoxazol-4-yl)-1*H*-benzo[d]imidazol-2-yl)piperidin-2-one;
- 10 (S)-6-(1-(3,3-difluorocyclobutyl)-5-(3,5-dimethylisoxazol-4-yl)-1*H*-benzo[d]imidazol-2-yl)-1-(3,4-difluorophenyl)piperidin-2-one ;
- (S)-6-(1-(3,3-difluorocyclobutyl)-5-(3,5-dimethylisoxazol-4-yl)-1*H*-benzo[d]imidazol-2-yl)-1-(3-fluoro-4-methoxyphenyl)piperidin-2-one;
- 15 (1*S*,4*r*)-methyl 4-(2-((*S*)-1-(3,4-difluorophenyl)-6-oxopiperidin-2-yl)-5-(3,5-dimethylisoxazol-4-yl)-1*H*-benzo[d]imidazol-1-yl)cyclohexanecarboxylate;
- (1*S*,4*r*)-4-(2-((*S*)-1-(3,4-difluorophenyl)-6-oxopiperidin-2-yl)-5-(3,5-dimethylisoxazol-4-yl)-1*H*-benzo[d]imidazol-1-yl)cyclohexane carboxylic acid ;
- (1*S*,4*r*)-4-(2-((*S*)-1-(3,4-difluorophenyl)-6-oxopiperidin-2-yl)-5-(3,5-dimethylisoxazol-4-yl)-1*H*-benzo[d]imidazol-1-yl)-*N*-propylcyclohexane carboxamide;
- 20 (1*S*,4*r*)-4-(2-((*S*)-1-(3,4-difluorophenyl)-6-oxopiperidin-2-yl)-5-(3,5-dimethylisoxazol-4-yl)-1*H*-benzo[d]imidazol-1-yl)-*N*-methyl-*N*-propylcyclohexanecarboxamide;
- (S)-6-(1-(4,4-difluorocyclohexyl)-5-(3,5-dimethylisoxazol-4-yl)-1*H*-benzo[d]imidazol-2-yl)-1-(6-fluoropyridin-3-yl)piperidin-2-one;
- 25 (S)-6-(1-(4,4-difluorocyclohexyl)-5-(3,5-dimethylisoxazol-4-yl)-1*H*-benzo[d]imidazol-2-yl)-1-(5-fluoropyridin-3-yl)piperidin-2-one;
- (S)-6-(1-(4,4-difluorocyclohexyl)-5-(3,5-dimethylisoxazol-4-yl)-1*H*-benzo[d]imidazol-2-yl)-1-(pyridin-3-yl)piperidin-2-one;

(S)-1-(3-chloro-4-methoxyphenyl)-6-(6-(3,5-dimethylisoxazol-4-yl)-3-((1*r*,4*S*)-4-hydroxycyclohexyl)-3*H*-imidazo[4,5-*b*]pyridin-2-yl)piperidin-2-one;

(S)-1-(3,4-difluorophenyl)-6-(6-(3,5-dimethylisoxazol-4-yl)-3-((1*r*,4*S*)-4-hydroxycyclohexyl)-3*H*-imidazo[4,5-*b*]pyridin-2-yl)piperidin-2-one;

5 (S)-6-(6-(3,5-dimethylisoxazol-4-yl)-3-((1*r*,4*S*)-4-hydroxycyclohexyl)-3*H*-imidazo[4,5-*b*]pyridin-2-yl)-1-(3-fluoro-4-methoxyphenyl)piperidin-2-one;

(S)-1-(3-chloro-4-methoxyphenyl)-5-(3-(4,4-difluorocyclohexyl)-6-(3,5-dimethylisoxazol-4-yl)-3*H*-imidazo[4,5-*b*]pyridin-2-yl)pyrrolidin-2-one;

10 (S)-5-(3-(4,4-difluorocyclohexyl)-6-(3,5-dimethylisoxazol-4-yl)-3*H*-imidazo[4,5-*b*]pyridin-2-yl)-1-(3,4-difluorophenyl)pyrrolidin-2-one;

(S)-5-(3-(4,4-difluorocyclohexyl)-6-(3,5-dimethylisoxazol-4-yl)-3*H*-imidazo[4,5-*b*]pyridin-2-yl)-1-(3-fluoro-4-methoxyphenyl)pyrrolidin-2-one ;

(S)-6-(1-(4,4-difluorocyclohexyl)-5-(3,5-dimethylisoxazol-4-yl)-1*H*-benzo[*d*]imidazol-2-yl)-1-(pyrimidin-5-yl)piperidin-2-one;


15 (S)-1-(3,4-difluorophenyl)-6-(6-(3,5-dimethylisoxazol-4-yl)-3-isobutyl-3*H*-imidazo[4,5-*b*]pyridin-2-yl)piperidin-2-one; and

(S)-6-(6-(3,5-dimethylisoxazol-4-yl)-3-isobutyl-3*H*-imidazo[4,5-*b*]pyridin-2-yl)-1-(3-fluoro-4-methoxyphenyl)piperidin-2-one;

20 (S)-1-benzyl-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((1*r*,4*S*)-4-methoxycyclohexyl)-1*H*-benzo[*d*]imidazol-2-yl)pyrrolidin-2-one


and the pharmaceutically acceptable salts thereof.

6. A process for producing a compound as defined in Claim 1, which process comprises treating a compound of formula (II):



in which each of R, R⁰, R¹, W and Y is as defined in Claim 1, with a boronic acid of formula R²-B(OH)₂ in which R² is as defined in Claim 1, in the presence of Pd(PPh₃)₄ and Na₂CO₃ in aqueous ethanol; or .

- 5 treating a compound of formula (III):



in which each of R, R⁰, R¹, R², W and Y is as defined in Claim 1, with acetic acid at 60 - 100°C or HCl/1,4-dioxane 20 – 90%; or

- 10 treating a compound of formula (II) as defined above with a compound of formula R²-CH₂Br in which R² is as defined in Claim 1.

7. A process according to Claim 6, which further comprises converting the resulting arylimidazolyl isoxazole of formula (I) into a pharmaceutically acceptable salt thereof.
8. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier or diluent and, as an active ingredient, a compound as defined in any of Claims 1 to 5.
- 15 9. A compound as defined in any of Claims 1 to 5 for use in the treatment of the human or animal body by therapy.
10. A compound as defined in any of Claims 1 to 5 for use in treating cancer.

11. A compound for use according to Claim 10, in which the cancer is a cancer that expresses AR, a cancer that expresses c-Myc, a tumour that harbours loss of function mutations in CBP or p300 or a cancer in which there is activation of CBP and/or p300 function.
- 5 12. Use of a compound as defined in any of Claims 1 to 5 in the manufacture of a medicament for use in treating cancer.
13. Use according to Claim 12, in which the cancer is a cancer that expresses AR, a cancer that expresses c-Myc, a tumour that harbours loss of function mutations in CBP or p300 or a cancer in which there is activation of CBP and/or p300 function.
- 10 14. A product comprising
- (i) a compound as defined in any of Claims 1 to 5; and
 - (ii) one or more other therapeutic agent or agents;
- for separate, simultaneous or sequential administration in the prophylactic or therapeutic treatment of cancer.
- 15 15. A product according to Claim 14 in which the or each other therapeutic agent is selected from androgen receptor antagonists; inhibitors of CYP17A1 (17 α -hydroxylase/C17,20 lyase); cytotoxic chemotherapeutic agents; immune checkpoint inhibitors; inhibitors of PARP (poly ADP ribose polymerase); and inhibitors of CDK4/6 (cyclin-dependant kinase 4 and 6).